Multiple Sclerosis Research Today is a free monthly online journal that collates and summarizes the latest research about Multiple Sclerosis, including details on diagnosis, symptoms, treatment, prognosis.

Volume 6 (2009), Issue 8 (August)

1. Interferon-beta(1b) treatment in neuromyelitis optica.
   Eur Neurol, 62(3): 167-70. [Abstract] [Full-text]
2. Relationship between psychosocial factors and onset of multiple sclerosis.
   Eur Neurol, 62(3): 130-6. [Abstract] [Full-text]
3. Symptom cluster as a predictor of physical activity in multiple sclerosis: preliminary evidence.
   J Pain Symptom Manage, 38(2): 270-80. [Abstract] [Full-text]
4. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity.
   Neurology, 73(5): 372-7. [Abstract] [Full-text]
5. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab.
   Arch Neurol, 66(8): 1016-20. [Abstract] [Full-text]
6. Damage to the optic radiation in multiple sclerosis is associated with retinal injury and visual disability.
   Arch Neurol, 66(8): 998-1006. [Abstract] [Full-text]
7. Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis.
   Arch Neurol, 66(8): 972-8. [Abstract] [Full-text]
8. Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults.
   Arch Neurol, 66(8): 967-71. [Abstract] [Full-text]
9. Neuromyelitis optica IgG serostatus in fulminant central nervous system inflammatory demyelinating disease.
   Arch Neurol, 66(8): 964-6. [Abstract] [Full-text]
10. Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab.
    Mult Scler, 15(8): 1006-8. [Abstract] [Full-text]
11. Subjective fatigue is not associated with cognitive impairment in multiple sclerosis: cross-sectional and longitudinal analysis.
    Mult Scler, 15(8): 998-1005. [Abstract] [Full-text]
12. Assessing disability progression with the Multiple Sclerosis Functional Composite.
    Mult Scler, 15(8): 984-97. [Abstract] [Full-text]
13. Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression?
    Mult Scler, 15(8): 959-64. [Abstract] [Full-text]
14. Magnetic resonance evidence of cortical onset of multiple sclerosis.
    Mult Scler, 15(8): 933-41. [Abstract] [Full-text]
15. Multiple sclerosis risk in radiologically uncovered asymptomatic possible inflammatory-demyelinating disease.
    Mult Scler, 15(8): 918-27. [Abstract] [Full-text]
16. Serum leptin levels during pregnancy in multiple sclerosis.
    Mult Scler, 15(8): 907-12. [Abstract] [Full-text]
17. Allergy and multiple sclerosis: a population-based case-control study.
    Mult Scler, 15(8): 899-906. [Abstract] [Full-text]
18. Explaining multiple sclerosis prevalence by ultraviolet exposure: a geospatial analysis.
    Mult Scler, 15(8): 891-8. [Abstract] [Full-text]
19. Altered innate immune response of plasmacytoid dendritic cells in multiple sclerosis.
    Clin Exp Immunol, 157(3): 332-42. [Abstract] [Full-text]
20. Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis.
    J Neuroimmunol, 213(1): 123-30. [Abstract] [Full-text]
21. Oxygen radical production in leukocytes and disease severity in multiple sclerosis.
    J Neuroimmunol, 213(1): 131-4. [Abstract] [Full-text]
22. Neuroprotective effects of the complement terminal pathway during demyelination: implications for oligodendrocyte survival.
    J Neuroimmunol, 213(1): 3-11. [Abstract] [Full-text]
23. Long-term follow-up of benign multiple sclerosis in Hordaland County, Western Norway.
    Mult Scler, 15(8): 942-50. [Abstract] [Full-text]
24. Acute neuroinflammation in Lewis rats - a model for acute multiple sclerosis relapses.
    J Neuroimmunol, 213(1): 84-90. [Abstract] [Full-text]
25. Glypican 5 is an interferon-beta response gene: a replication study.
    Mult Scler, 15(8): 913-7. [Abstract] [Full-text]
26. Peripheral blood regulatory T cell measurements correlate with serum vitamin D levels in patients with multiple sclerosis.
    J Neuroimmunol, 213(1): 135-41. [Abstract] [Full-text]
27. Genetic association between polymorphisms in the BTG1 gene and multiple sclerosis.
    J Neuroimmunol, 213(1): 142-7. [Abstract] [Full-text]
28. Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis.
    Arch Neurol, 66(8): 958-63. [Abstract] [Full-text]
29. Fellow eye changes in optic neuritis correlate with the risk of multiple sclerosis.
    Mult Scler, 15(8): 928-32. [Abstract] [Full-text]
30. High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study.
    Mult Scler, 15(8): 977-83. [Abstract] [Full-text]
31. Clinical trials of multiple sclerosis therapies: improvements to demonstrate long-term patient benefit.
    Mult Scler, 15(8): 951-8. [Abstract] [Full-text]
32. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
    Mult Scler, 15(8): 965-76. [Abstract] [Full-text]
33. Tissue-specific imaging is a robust methodology to differentiate in vivo T1 black holes with advanced multiple sclerosis-induced damage.
    AJNR Am J Neuroradiol, 30(7): 1394-401. [Abstract] [Full-text]
34. Thalamic involvement and its impact on clinical disability in patients with multiple sclerosis: a diffusion tensor imaging study at 3T.
    AJNR Am J Neuroradiol, 30(7): 1380-6. [Abstract] [Full-text]
35. Treatment with rapamycin ameliorates clinical and histological signs of protracted relapsing experimental allergic encephalomyelitis in Dark Agouti rats and induces expansion of peripheral CD4+CD25+Foxp3+ regulatory T cells.
    J Autoimmun, 33(2): 135-40. [Abstract] [Full-text]
36. Interferon beta induces mature dendritic cell apoptosis through caspase-11/caspase-3 activation.
    Blood, 114(7): 1344-54. [Abstract] [Full-text]
37. Lower fractional anisotropy at the anterior body of the normal-appearing corpus callosum in multiple sclerosis versus symptomatic carotid occlusion.
    Neuroradiology, 51(9): 557-61. [Abstract] [Full-text]
38. Distinctive retinal nerve fibre layer and vascular changes in neuromyelitis optica following optic neuritis.
    J Neurol Neurosurg Psychiatry, 80(9): 1002-5. [Abstract] [Full-text]
39. Responsiveness of patient reported outcome measures in multiple sclerosis relapses: the REMS study.
    J Neurol Neurosurg Psychiatry, 80(9): 1023-8. [Abstract] [Full-text]
40. The challenge of follow-on biologics for treatment of multiple sclerosis.
    Neurology, 73(7): 552-9. [Abstract] [Full-text]
41. Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis.
    Neurology, 73(7): 504-10. [Abstract] [Full-text]
42. Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis.
    Neurology, 73(7): 498-503. [Abstract] [Full-text]
43. Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation?
    Expert Opin Drug Deliv, 6(9): 995-1002. [Abstract] [Full-text]
44. Multiple sclerosis: human model for EAE?
    Eur J Immunol, 39(8): 2036-9. [Abstract] [Full-text]
45. Mechanisms of primary axonal damage in a viral model of multiple sclerosis.
    J Neurosci, 29(33): 10272-80. [Abstract] [Full-text]
46. Multiple sclerosis and neurofibromatosis type 1: report of seven patients from Iran.
    Mult Scler, 15(9): 1126-30. [Abstract] [Full-text]
47. Sjogren's syndrome myelopathy: spinal cord involvement in Sjogren's syndrome might be a manifestation of neuromyelitis optica.
    Mult Scler, 15(9): 1062-8. [Abstract] [Full-text]
48. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study.
    Mult Scler, 15(9): 1037-42. [Abstract] [Full-text]
49. Molecular and immunogenic features of myelin lipids: incitants or modulators of multiple sclerosis?
    Mult Scler, 15(9): 1011-29. [Abstract] [Full-text]
50. Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE.
    Nat Immunol, 10(9): 958-64. [Abstract] [Full-text]
51. A comparison of 3T and 7T in the detection of small parenchymal veins within MS lesions.
    Invest Radiol, 44(9): 491-4. [Abstract] [Full-text]
52. Foreign accent syndrome as a first sign of multiple sclerosis.
    Mult Scler, 15(9): 1123-5. [Abstract] [Full-text]
53. Extensive vasogenic edema of anti-aquaporin-4 antibody-related brain lesions.
    Mult Scler, 15(9): 1113-7. [Abstract] [Full-text]
54. Multiple sclerosis risk: interaction between human leukocyte antigen and the environment in Sardinian population.
    Mult Scler, 15(9): 1030-6. [Abstract] [Full-text]
55. Suspected multiple sclerosis - what to do? Evaluation of a patient information leaflet.
    Mult Scler, 15(9): 1103-12. [Abstract] [Full-text]
56. Brain abnormalities in Sjogren syndrome with recurrent CNS manifestations: association with neuromyelitis optica.
    Mult Scler, 15(9): 1069-76. [Abstract] [Full-text]
57. Dose-dependent melanonychia by mitoxantrone.
    Mult Scler, 15(9): 1131-2. [Abstract] [Full-text]
58. Gadolinium-enhancing or active T2 magnetic resonance imaging lesions in multiple sclerosis clinical trials?
    Mult Scler, 15(9): 1043-7. [Abstract] [Full-text]
59. Quantitative assessment of brain iron by R(2)* relaxometry in patients with clinically isolated syndrome and relapsing-remitting multiple sclerosis.
    Mult Scler, 15(9): 1048-54. [Abstract] [Full-text]
60. The development of patient-reported outcome indices for multiple sclerosis (PRIMUS).
    Mult Scler, 15(9): 1092-102. [Abstract] [Full-text]
61. Cognitive dysfunction in primary progressive multiple sclerosis: a neuropsychological and MRI study.
    Mult Scler, 15(9): 1055-61. [Abstract] [Full-text]
62. Home administration of intravenous methylprednisolone for multiple sclerosis relapses: the experience of French multiple sclerosis networks.
    Mult Scler, 15(9): 1085-91. [Abstract] [Full-text]
63. Sensitivity of conventional memory tests in multiple sclerosis: comparing the Rao Brief Repeatable Neuropsychological Battery and the Minimal Assessment of Cognitive Function in MS.
    Mult Scler, 15(9): 1077-84. [Abstract] [Full-text]
64. HLA-DQB1*0602 determines disease susceptibility in a new "humanized" multiple sclerosis model in HLA-DR15 (DRB1*1501;DQB1*0602) transgenic mice.
    J Immunol, 183(5): 3531-41. [Abstract] [Full-text]
65. Corpus callosum function in verbal dichotic listening: inferences from a longitudinal follow-up of Relapsing-Remitting Multiple Sclerosis patients.
    Brain Lang, 110(2): 101-5. [Abstract] [Full-text]
66. The role of specialist and general nurses working with people with multiple sclerosis.
    J Clin Nurs, 18(18): 2635-48. [Abstract] [Full-text]
67. B-type natriuretic peptide as a marker of subclinical heart injury during mitoxantrone therapy in MS patients--preliminary study.
    Clin Neurol Neurosurg, 111(8): 676-8. [Abstract] [Full-text]
68. A longitudinal analysis of cognitive dysfunction, coping, and depression in multiple sclerosis.
    Neuropsychology, 23(5): 581-91. [Abstract] [Full-text]
69. Parent-of-origin effect in multiple sclerosis: observations from interracial matings.
    Neurology, 73(8): 602-5. [Abstract] [Full-text]
70. Urinary dysfunction in multiple sclerosis.
    J Clin Neurosci, 16(10): 1321-4. [Abstract] [Full-text]
71. Clinical implications of a possible role of vitamin D in multiple sclerosis.
    J Neurol, 256(9): 1468-79. [Abstract] [Full-text]
72. Migration and multiple sclerosis in Alaskan military veterans.
    J Neurol, 256(9): 1413-7. [Abstract] [Full-text]
73. Quantification and clinical relevance of brain atrophy in multiple sclerosis: a review.
    J Neurol, 256(9): 1397-412. [Abstract] [Full-text]
74. Vibration therapy in multiple sclerosis: a pilot study exploring its effects on tone, muscle force, sensation and functional performance.
    Clin Rehabil, 23(9): 771-81. [Abstract] [Full-text]
75. Memory and naïve B-cell subsets in patients with multiple sclerosis.
    Neurosci Lett, 464(1): 74-8. [Abstract] [Full-text]
76. Aquaporin-4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies.
    Glia, 57(13): 1363-73. [Abstract] [Full-text]

© 2004-2012 Multiple Sclerosis Research Today. All Rights Reserved.